Trial · NCT00773513
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and Date of Death or Non-Fatal Cardiovascular Events, Whichever Occurred First | Erythropoiesis Stimulating Agents | 5.1 | 95% Confidence Interval 4.8 to 5.6 | years | |
Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and Date of Death or Non-Fatal Cardiovascular Events, Whichever Occurred First | Methoxy Polyethylene Glycol-Epoetin Beta | 5.1 | 95% Confidence Interval 4.7 to 5.4 | years | |
| Time to All-Cause Mortality | Erythropoiesis Stimulating Agents | 6.1 | 95% Confidence Interval 5.6 to 6.5 | years | |
| Time to All-Cause Mortality | Methoxy Polyethylene Glycol-Epoetin Beta | 5.9 | 95% Confidence Interval 5.5 to 6.5 | years | |
| Time to Non-Fatal and Fatal Myocardial Infarction | Erythropoiesis Stimulating Agents | NA | 95% Confidence Interval NA to NA | years | |
| Time to Non-Fatal and Fatal Myocardial Infarction | Methoxy Polyethylene Glycol-Epoetin Beta | NA | 95% Confidence Interval NA to NA | years | |
| Time to Non-Fatal and Fatal Stroke | Erythropoiesis Stimulating Agents | NA | 95% Confidence Interval NA to NA | years | |
| Time to Non-Fatal and Fatal Stroke | Methoxy Polyethylene Glycol-Epoetin Beta | NA | 95% Confidence Interval NA to NA | years | |
| Time to Non-Fatal Cardiovascular Events (Myocardial Infarction or Stroke, Whichever Occurred First) | Erythropoiesis Stimulating Agents | NA | 95% Confidence Interval NA to NA | years | |
| Time to Non-Fatal Cardiovascular Events (Myocardial Infarction or Stroke, Whichever Occurred First) | Methoxy Polyethylene Glycol-Epoetin Beta | NA | 95% Confidence Interval NA to NA | years | |
| Percentage of Participants With Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia (PRCA) | Erythropoiesis Stimulating Agents | 0 | percentage of participants | ||
| Percentage of Participants With Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia (PRCA) | Methoxy Polyethylene Glycol-Epoetin Beta | 0 | percentage of participants | ||
| Percentage of Participants With Gastrointestinal Bleeding | Erythropoiesis Stimulating Agents | 11.1 | percentage of participants | ||
| Percentage of Participants With Gastrointestinal Bleeding | Methoxy Polyethylene Glycol-Epoetin Beta | 11.7 | percentage of participants | ||
| Percentage of Participants With Thromboembolic Events | Erythropoiesis Stimulating Agents | 34.5 | percentage of participants | ||
| Percentage of Participants With Thromboembolic Events | Methoxy Polyethylene Glycol-Epoetin Beta | 32.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00773513/results